오믹스 기반 임상시험 시장 - 세계 산업 규모, 점유율, 동향, 기회, 예측 : 단계별, 연구 디자인별, 적응증별, 지역별＆경쟁(2021-2031년)

The Global Omics-Based Clinical Trials Market is projected to grow from USD 27.23 Billion in 2025 to USD 41.53 Billion by 2031, at a 7.29% CAGR. These trials leverage high-throughput technologies like genomics, proteomics, and metabolomics for patient stratification and biomarker identification. Key growth drivers include the critical shift towards precision medicine for improved therapeutic outcomes, alongside decreasing high-throughput sequencing costs and regulatory encouragement for biomarker-driven drug development. While personalized medicines represented about 38 percent of newly approved therapeutics in 2024, the market faces challenges in seamlessly integrating complex multi-dimensional data into standardized clinical workflows, requiring substantial infrastructure for validation and analysis across diverse populations, thus hindering broader scalability.

Market Driver

The accelerated adoption of precision and personalized medicine strategies is a primary catalyst for the Global Omics-Based Clinical Trials Market, fundamentally transforming drug development by enabling treatments tailored to specific genetic profiles and improving patient stratification with biomarkers to reduce trial failure rates. This trend is particularly evident in oncology, where genomic profiling is standard, as demonstrated by the FDA's approval of 17 novel oncology drugs in 2024. Concurrently, the integration of artificial intelligence for complex multi-omics data analysis addresses data interpretation bottlenecks by rapidly identifying non-obvious correlations in vast datasets, significantly expediting discovery. This technological synergy attracts substantial investment, exemplified by J.P. Morgan's projection of NVIDIA's healthcare AI sector contributing $1 billion in recurring revenue by 2025, which collectively drives broader industry growth and increased R&D spending, such as AstraZeneca's 24 percent rise in 2024.

Market Challenge

The most significant impediment to the growth of the Global Omics-Based Clinical Trials Market is the technical and operational complexity of integrating high-volume multi-dimensional biological data from genomics, proteomics, and metabolomics into standardized clinical workflows. This necessitates substantial infrastructure and advanced bioinformatic capabilities, which many clinical research sites lack, creating bottlenecks that lead to prolonged study timelines and inflated operational costs. This friction limits the scalability of precision medicine initiatives, especially for smaller sponsors, and increases the failure rate of study initiation and execution, with 38 percent of clinical research sites identifying rising protocol complexity as a primary operational challenge in 2024. Consequently, research sites overwhelmed by data requirements experience slower patient recruitment and increased data quality risks, delaying regulatory approvals and dampening the commercial adoption of omics-driven clinical strategies.

Market Trends

Current market trends include the widespread adoption of single-cell sequencing and spatial omics technologies, which are revolutionizing clinical trial design by enabling high-resolution profiling of cellular heterogeneity. These tools precisely map the tumor microenvironment and immune responses at the individual cell level, enhancing the identification of resistance mechanisms and predictive biomarkers with unprecedented accuracy, thereby improving the granularity of biological data in drug development. The rapid uptake is evident, with 10x Genomics reporting its cumulative instrument base surpassed 7,000 units globally by January 2025. Simultaneously, omics research is strategically expanding beyond oncology into autoimmune and rare disease indications, where sponsors increasingly leverage genomic and transcriptomic data to stratify heterogeneous patient populations and develop targeted RNA interference therapies for monogenic disorders. This shift, driven by multi-omics' growing capability to elucidate obscure disease pathways and validate novel targets in non-malignant conditions, creates a lucrative new frontier for clinical investigation, underscored by Alnylam Pharmaceuticals' 103 percent year-over-year increase in total net product revenues.

Key Market Players

• Parexel International Corporation
• Pharmaceutical Product Development (PPD)
• Charles River Laboratory
• ICON plc
• SGS SA
• Eli Lilly and Company
• Pfizer Inc.
• Covance Inc.
• Novo Nordisk
• Rebus Bio

Report Scope

In this report, the Global Omics-Based Clinical Trials Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Omics-Based Clinical Trials Market, By Phase

• Phase I
• Phase II
• Phase III
• Phase IV

Omics-Based Clinical Trials Market, By Study Design

• Expanded Access Studies
• Interventional Studies
• Observational Studies

Omics-Based Clinical Trials Market, By Indication

• Cardiology
• CNS Diseases
• Genetic Diseases
• Immunology
• Oncology
• Respiratory Diseases
• Skin Diseases

Omics-Based Clinical Trials Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Omics-Based Clinical Trials Market.

Available Customizations:

Global Omics-Based Clinical Trials Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Omics-Based Clinical Trials Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Phase (Phase I, Phase II, Phase III, Phase IV)
  • 5.2.2. By Study Design (Expanded Access Studies, Interventional Studies, Observational Studies)
  • 5.2.3. By Indication (Cardiology, CNS Diseases, Genetic Diseases, Immunology, Oncology, Respiratory Diseases, Skin Diseases)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Omics-Based Clinical Trials Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Phase
  • 6.2.2. By Study Design
  • 6.2.3. By Indication
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Omics-Based Clinical Trials Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Phase
      • 6.3.1.2.2. By Study Design
      • 6.3.1.2.3. By Indication
  • 6.3.2. Canada Omics-Based Clinical Trials Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Phase
      • 6.3.2.2.2. By Study Design
      • 6.3.2.2.3. By Indication
  • 6.3.3. Mexico Omics-Based Clinical Trials Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Phase
      • 6.3.3.2.2. By Study Design
      • 6.3.3.2.3. By Indication

7. Europe Omics-Based Clinical Trials Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Phase
  • 7.2.2. By Study Design
  • 7.2.3. By Indication
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Omics-Based Clinical Trials Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Phase
      • 7.3.1.2.2. By Study Design
      • 7.3.1.2.3. By Indication
  • 7.3.2. France Omics-Based Clinical Trials Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Phase
      • 7.3.2.2.2. By Study Design
      • 7.3.2.2.3. By Indication
  • 7.3.3. United Kingdom Omics-Based Clinical Trials Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Phase
      • 7.3.3.2.2. By Study Design
      • 7.3.3.2.3. By Indication
  • 7.3.4. Italy Omics-Based Clinical Trials Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Phase
      • 7.3.4.2.2. By Study Design
      • 7.3.4.2.3. By Indication
  • 7.3.5. Spain Omics-Based Clinical Trials Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Phase
      • 7.3.5.2.2. By Study Design
      • 7.3.5.2.3. By Indication

8. Asia Pacific Omics-Based Clinical Trials Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Phase
  • 8.2.2. By Study Design
  • 8.2.3. By Indication
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Omics-Based Clinical Trials Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Phase
      • 8.3.1.2.2. By Study Design
      • 8.3.1.2.3. By Indication
  • 8.3.2. India Omics-Based Clinical Trials Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Phase
      • 8.3.2.2.2. By Study Design
      • 8.3.2.2.3. By Indication
  • 8.3.3. Japan Omics-Based Clinical Trials Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Phase
      • 8.3.3.2.2. By Study Design
      • 8.3.3.2.3. By Indication
  • 8.3.4. South Korea Omics-Based Clinical Trials Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Phase
      • 8.3.4.2.2. By Study Design
      • 8.3.4.2.3. By Indication
  • 8.3.5. Australia Omics-Based Clinical Trials Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Phase
      • 8.3.5.2.2. By Study Design
      • 8.3.5.2.3. By Indication

9. Middle East & Africa Omics-Based Clinical Trials Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Phase
  • 9.2.2. By Study Design
  • 9.2.3. By Indication
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Omics-Based Clinical Trials Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Phase
      • 9.3.1.2.2. By Study Design
      • 9.3.1.2.3. By Indication
  • 9.3.2. UAE Omics-Based Clinical Trials Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Phase
      • 9.3.2.2.2. By Study Design
      • 9.3.2.2.3. By Indication
  • 9.3.3. South Africa Omics-Based Clinical Trials Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Phase
      • 9.3.3.2.2. By Study Design
      • 9.3.3.2.3. By Indication

10. South America Omics-Based Clinical Trials Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Phase
  • 10.2.2. By Study Design
  • 10.2.3. By Indication
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Omics-Based Clinical Trials Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Phase
      • 10.3.1.2.2. By Study Design
      • 10.3.1.2.3. By Indication
  • 10.3.2. Colombia Omics-Based Clinical Trials Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Phase
      • 10.3.2.2.2. By Study Design
      • 10.3.2.2.3. By Indication
  • 10.3.3. Argentina Omics-Based Clinical Trials Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Phase
      • 10.3.3.2.2. By Study Design
      • 10.3.3.2.3. By Indication

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Omics-Based Clinical Trials Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Parexel International Corporation
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Pharmaceutical Product Development (PPD)
• 15.3. Charles River Laboratory
• 15.4. ICON plc
• 15.5. SGS SA
• 15.6. Eli Lilly and Company
• 15.7. Pfizer Inc.
• 15.8. Covance Inc.
• 15.9. Novo Nordisk
• 15.10. Rebus Bio

16. Strategic Recommendations

17. About Us & Disclaimer